Login (DCU Staff Only)
Login (DCU Staff Only)

DORAS | DCU Research Repository

Explore open access research and scholarly works from DCU

Advanced Search

Novel targeted agents in Her-2 positive and triple negative breast cancer

Tryfonopoulos, Dimitrios (2013) Novel targeted agents in Her-2 positive and triple negative breast cancer. Master of Science thesis, Dublin City University.

Abstract
The development of Her-2 targeted therapies has improved the prognosis for patients with Her-2 positive breast cancer. However, not all Her-2 positive tumours respond to treatment with Her-2 antagonists. Triple negative cancers are resistant to hormone and Her-2 targeted therapies. This project focused on improving response in Her-2 overexpressing breast cancer and on developing effective targeted therapy strategies for triple negative breast cancer. We tested a number of multi-target kinase inhibitors (imatinib, sunitinib, pazopanib and dasatinib) in Her-2 positive and triple negative breast cancer cell lines, alone and in combination with other agents. Two of the Her-2 positive cell lines showed moderate sensitivity to sunitinib malate. Combined treatment with sunitinib and trastuzumab showed improved response compared to either drug alone, in the four Her-2 positive cell lines tested. Dasatinib inhibited growth in 3 of the 5 triple negative but in only 1 of the 4 Her-2 positive cell lines tested. Based on response to the other multi-target kinase inhibitors, which have overlapping target specificities, and the Src,PP2, our results suggest that sensitivity to dasatinib in triple negative breast cancer is due to inhibition of ephrin type A receptors. Consistent with this hypothesis, neither Src expression nor phosphorylation predicted sensitivity to dasatinib, but high levels of Ephrin type A receptor 2 protein correlated with dasatinib sensitivity. High levels of caveolin 1 and caveolin 2 also correlated with dasatinib sensitivity in the panel of cell lines. Dasatinib combined with cisplatin was synergistic in the three dasatinib-sensitive cell lines. Dasatinib, in combination with 5’-deoxy-5’-fluoruridine, displayed synergy or additivity. Moderate synergy was observed with docetaxel in two triple negative cell lines. In conclusion, we have identified dasatinib with cisplatin as a rational combination for testing in triple-negative breast cancer, and have identified a panel of putative predictive biomarkers for dasatinib sensitivity (EphA2, CAV1 and CAV2).
Metadata
Item Type:Thesis (Master of Science)
Date of Award:November 2013
Refereed:No
Supervisor(s):O'Donovan, Norma
Uncontrolled Keywords:HER2 positive; triple negative; breast cancer; dasatinib
Subjects:Biological Sciences > Cell biology
Medical Sciences > Cancer
DCU Faculties and Centres:DCU Faculties and Schools > Faculty of Science and Health > School of Biotechnology
Research Initiatives and Centres > National Institute for Cellular Biotechnology (NICB)
Use License:This item is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. View License
Funders:Health Research Board, Cancer Clinical Research Trust
ID Code:18334
Deposited On:22 Nov 2013 14:17 by Norma O'Donovan . Last Modified 19 Jul 2018 14:59
Documents

Full text available as:

[thumbnail of MSc thesis]
Preview
PDF (MSc thesis) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
Downloads

Downloads

Downloads per month over past year

Archive Staff Only: edit this record